The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAquis Exchange Regulatory News (AQX)

Share Price Information for Aquis Exchange (AQX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 468.00
Bid: 460.00
Ask: 470.00
Change: 3.00 (0.65%)
Spread: 10.00 (2.174%)
Open: 465.00
High: 468.00
Low: 468.00
Prev. Close: 465.00
AQX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AQSE expands research for its top-tier stocks

27 May 2021 07:00

RNS Number : 9449Z
Aquis Exchange PLC
27 May 2021
 

RNS Reach

27 May 2021

Aquis Exchange PLC

("Aquis" or the "Company")

AQSE expands research for its top-tier stocks

AQSE adds quantitative research by Fregnan for Apex stocks and enters partnership with Research Tree to provide portal for existing fundamental research on Apex stocks

 

Aquis Exchange PLC (AQX.L), the exchange services group, is pleased to announce that its equities listing division Aquis Stock Exchange (AQSE) has entered into arrangements with Fregnan Ltd and Research Tree Ltd. to produce and publish research on AQSE's top-tier Apex stocks.

AQSE recognises that research is a very important component of the decision-making process around the purchase and sale of stocks. In recent years, research has been declining, particularly in small and mid-cap stocks. At the time of its acquisition of AQSE, Aquis stated that one of its aims for the new business was to address this lack of research. Today's announcement is a great step forward in the fulfilment of that undertaking, as every Apex stock will now have quantitative research, provided by Fregnan, available for free on it through the AQSE website. In addition, any existing fundamental research on Apex stocks will also be available through the new, dedicated, Research Tree portal.

Fregnan produces high quality, unbiased financial analysis and models through automation at scale. It uses advances machine learning and artificial intelligence to bring unique insights that traditional techniques do not uncover. Research Tree is an independent company, which provides investors with up-to-date and historical professional equity research and stock reports from a variety of brokers and research houses.

Since Aquis acquired AQSE (previously known as NEX Exchange Ltd and owned by CME Inc.) in March 2020, a major transformation of the business has been underway. At the time of the acquisition, Aquis said it would look to make three major changes to the business: increase institutional and retail investment into AQSE, raise standards and boost liquidity. In the last year, it has introduced segmentation by dividing the Growth Market into the Apex and Access sections and raised standards by introducing its Growth Prospectus for Apex stocks and compelling companies to sign up to a reputable corporate governance code. It has also introduced a short selling ban to protect businesses and long-term investors, as well as a market-maker scheme that has narrowed spreads and increased liquidity. Further, the Company has installed its proprietary state-of-art technology and is working with the top on-line private client brokers to improve their electronic connectivity to AQSE.

 

Commenting on the deal, Aquis Exchange CEO Alasdair Haynes said:

"The plans we are unveiling today for expanding the research provided on AQSE-quoted stocks fulfils yet another of the promises we made when we bought this business and takes us further along the journey of making AQSE into the most appropriate and best home for growth companies. We look forward to a long and fruitful collaboration with both Fregnan and Research Tree."

 

Fregnan CEO and co-Founder, Vince Julier, added:

"This collaboration highlights the power of bringing together two technologically-driven companies to transform the process of valuing a company and generating new insights to the benefit of market participants. We are thrilled that our collaboration with AQSE, with their focus on growth companies, further highlights the critical role that the technology, particularly advanced machine learning and artificial intelligence, is now playing in investment analysis, research or stock selection."

 

Research Tree's CEO and co-Founder, Rob Mundy, said:

"We are delighted to announce our partnership with AQSE. This agreement is welcome recognition that our current offering and future product pipeline adds good value to all stakeholders. At Research Tree our primary focus is to help markets operate more efficiently by better connecting investors, quoted companies, research providers and stock exchanges. Our growing provision of research, events and infrastructure therefore aligns perfectly with AQSE and its exciting future plans."

 

For more information please contact:

Aquis Exchange PLC

Tel: +44 (0)7768 078 110

Belinda Keheyan, Head of Marketing

Research Tree Limited

Robert Mundy

robert.mundy@research-tree.com

Fregnan Limited

Tel: +44 (0)7768 142 728

Vincent Julier

Liberum Capital Limited (Nominated Adviser and Joint Broker)

Tel: +44 (0) 20 3100 2000

Chris Clarke

Clayton Bush

Edward Thomas

Kane Collings

Canaccord Genuity Limited (Joint Broker)

Tel: +44 (0) 20 7523 8000

Emma Gabriel (Corporate Broking)

Jeremy Grime (Specialist Sales)

Alma PR (Financial PR Adviser)

Tel: +44 (0)20 3405 0209

Susie Hudson

aquis@almapr.co.uk

Kieran Breheny

Faye Calow

 

Notes to Editors

 

About Aquis Exchange

Aquis Exchange PLC is an exchange services group, which operates pan-European cash equities trading businesses (Aquis Exchange), growth and regulated primary markets (Aquis Stock Exchange/AQSE) and develops/licenses exchange software to third parties (Aquis Technologies).

Aquis Exchange is authorised and regulated by the UK Financial Conduct Authority and France's Autorité des Marchés Financiers to operate Multilateral Trading Facility businesses in the UK and in EU27 respectively. Aquis operates a lit order book and does not allow aggressive non-client proprietary trading, which has resulted in lower toxicity and signalling risk on Aquis than other trading venues in Europe. According to independent studies, trades on Aquis are less likely to lead to price movement than on other lit markets. Aquis uses a subscription pricing model which works by charging users according to the message traffic they generate, rather than a percentage of the value of each stock that they trade.

Aquis Stock Exchange (AQSE) is a stock market providing primary and secondary markets for equity and debt products. It is authorised as a Recognised Investment Exchange, which allows it to operate a regulated listings venue. AQSE, which used to be known as NEX Exchange Ltd., was acquired by Aquis in March 2020 from CME Inc. The AQSE Growth Market is divided into two segments 'Access' and 'Apex', with different levels of admission criteria. The Access market focuses on earlier stage growth companies, while Apex is the intended market for larger, more established businesses.

Aquis Technologies is the software and technology division of Aquis Exchange PLC. It creates and licenses cutting-edge, cost-effective matching engine and trade surveillance technology for banks, brokers, investment firms and exchanges.

Aquis Exchange PLC (AQX.L) is listed on the Alternative Investment Market of the LSE (AIM) market. For more information, please go to www.aquis.eu

 

About Fregnan

Fregnan is a fast-growing Fintech company that produces high quality unbiased models and forecasts through automation at scale, using advanced machine learning and artificial intelligence to bring unique insights that traditional models, using Excel do not surface. Fregnan also provides a powerful AI driven modelling tool that can be extensively tailored by the user to transform their process of developing a spreadsheet or valuing a company and getting insights from either.

Used by banks, fund managers, stock exchanges and research houses, this enables its clients to work faster and with more insight. With global coverage, access to over 80,000 stocks - from the smallest to the largest, and its ability to connect each model to any external data, such as ESG, Fregnan is transforming the investment research process.

For more information, please go to www.fregnan.com.

About Research Tree

Research Tree is a fast-growing platform that aggregates a range of research, video content and events from Banks, Brokers, Research Houses and other content providers. We make all this available to investors across our platform, our apps, and via our API and product suite to key distribution partners such as the LSE, on Broker Portals and on a growing number of company IR websites.

The platform offers real-time access to research from over 75 different Providers with more being added on a regular basis. Our current coverage includes over 90% of companies in the FTSE 100, c.80% of the FTSE 250 and c.80% of the AIM market, strong Scandinavian coverage, as well as a growing offering across the rest of Europe, the US and Canada.

www.research-tree.com | LinkedIn | Twitter

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASEIFIMEFSELI
Date   Source Headline
18th Apr 20242:30 pmRNSResult of AGM and Confirmation of Board Change
22nd Mar 20247:00 amRNSPublication of Annual Report and Notice of AGM
21st Mar 20247:00 amRNSResults for the year ended 31 December 2023
13th Mar 20247:00 amRNSContract with the Central Bank of Colombia
12th Mar 20247:00 amRNSAquis to Establish New Real Assets Market Segment
26th Feb 20247:00 amRNSAquis launches conditional order functionality
23rd Feb 20247:00 amRNSNotice of Results and Investor Presentation
25th Jan 20247:00 amRNSTrading Update and Notice of Results
23rd Jan 20243:15 pmRNSExercise of Share Options and Total Voting Rights
21st Dec 20231:15 pmRNSDirector/PDMR Notification
29th Nov 20237:00 amRNSAQSE becomes first cloud-based RIE
24th Nov 202312:00 pmRNSDirector/PDMR Notification
2nd Nov 20237:00 amRNSHolding(s) in Company
31st Oct 202311:55 amRNSBoard Change
18th Oct 20237:00 amRNSDirector/PDMR Shareholding
17th Oct 202312:39 pmRNSDirector/PDMR Shareholding
21st Sep 20237:00 amRNSInterim Results
12th Sep 20237:00 amRNSAquis Markets - Change to Proprietary Trading Rule
7th Sep 20237:00 amRNSNotice of Results and Investor Presentation
6th Sep 20237:00 amRNSAppointment of Nominated Adviser and Joint Broker
7th Aug 20232:15 pmRNSAcquisition of Minority Interest
28th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSAquis launches Dark to Lit Sweep
27th Apr 20237:00 amRNSDirector/PDMR Notification and Issue of Options
25th Apr 20232:18 pmRNSResult of AGM
14th Apr 20237:00 amRNSPublication of Annual Report & Notice of AGM
6th Apr 20231:05 pmRNSHolding(s) in Company
4th Apr 20237:00 amRNSDirector/PDMR Shareholding
3rd Apr 202310:55 amRNSDirector/PDMR Shareholding
3rd Apr 20237:01 amRNSDirector/PDMR Shareholdings
3rd Apr 20237:00 amRNSAquis Launches The World’s First 24x7 Exchange
30th Mar 20237:00 amRNSFinal Results
22nd Feb 20237:00 amRNSNotice of Results and Investor Presentation
2nd Feb 20237:00 amRNSExercise of Share Options & Total Voting Rights
2nd Feb 20237:00 amRNSExercise of Share Options & Total Voting Rights
26th Jan 20237:00 amRNSTrading Update and Notice of Results
5th Jan 20237:00 amRNSDirectorate Change
12th Dec 20227:00 amRNSIG Expands UK Trading Offering With AQSE Stocks
24th Nov 20229:13 amRNSDirector/PDMR Notification
23rd Nov 20224:09 pmRNSDirector/PDMR Notification
2nd Nov 20227:00 amRNSNotice of Capital Markets Day
27th Sep 20227:00 amRNSNotice of Capital Markets Day
22nd Sep 20227:00 amRNSInterim Results
5th Sep 202212:00 pmRNSLaunch of new EU dark pool, Aquis Matching Pool
23rd Aug 20227:00 amRNSNotice of Results
6th Jul 202212:00 pmRNSAPEX stocks now trading on Hargreaves Lansdown
30th Jun 202212:49 pmRNSDirector/PDMR Notification and Issue of Options
23rd Jun 20227:00 amRNSDirector/PDMR Shareholding
22nd Jun 202212:30 pmRNSExercise of Share Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.